INTERVIEW: Ally Bridge CEO On De-Risking China And Investing In 2016

With $1bn under management, the Hong Kong private equity firm Ally Bridge Group bagged multiple deals in 2015 including WuXi's $3.3bn privatization. CEO Frank Yu spoke to PharmAsia News about pursuing a holistic approach that goes beyond its China roots.

HONG KONG – Foreign investment in Asia’s life science companies is commonplace, but investment groups operating outside the region are often viewed as being less sophisticated or liable to put their money into areas where others fear to tread.

One company seeking to reverse this preconception is Ally Bridge Group (ABG), a pioneer of the “value added cross-border investment...

More from China

More from Focus On Asia